AI assistant
ImageneBio, Inc. — Director's Dealing 2021
Mar 26, 2021
34275_dirs_2021-03-25_11faa664-033b-49b9-bb1a-6b13abd9f645.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2021-03-25
Reporting Person: Ecsedy Jeffrey (Chief Scientific Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $2.94 | 2028-01-23 | Common Stock (63537) | Direct | |
| Stock Option (Right to Buy) | $2.15 | 2028-12-17 | Common Stock (37819) | Direct | |
| Stock Option (Right to Buy) | $4.15 | 2029-03-19 | Common Stock (79088) | Direct | |
| Stock Option (Right to Buy) | $7.87 | 2031-02-12 | Common Stock (191980) | Direct |
Footnotes
F1: 25% of this option vested and became exercisable on October 30, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F2: 25% of this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F3: 25% of this option vested and became exercisable on March 20, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F4: 25% of this option shall vest and become exercisable on February 12, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.